In the last trading session, 1.02 million shares of the Cg Oncology Inc (NASDAQ:CGON) were traded, and its beta was 1.56. Most recently the company’s share price was $20.06, and it changed around $0.78 or 4.05% from the last close, which brings the market valuation of the company to $1.53B. CGON currently trades at a discount to its 52-week high of $46.99, offering almost -134.25% off that amount. The share price’s 52-week low was $14.80, which indicates that the current value has risen by an impressive 26.22% since then. We note from Cg Oncology Inc’s average daily trading volume that its 10-day average is 1.74 million shares, with the 3-month average coming to 806.71K.
Cg Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended CGON as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Cg Oncology Inc is expected to report earnings per share of -0.28 for the current quarter.
Cg Oncology Inc (NASDAQ:CGON) trade information
Instantly CGON has showed a green trend with a performance of 4.05% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 20.48 on recent trading dayincreased the stock’s daily price by 2.05%. The company’s shares are currently down -30.06% year-to-date, but still up 18.56% over the last five days. On the other hand, Cg Oncology Inc (NASDAQ:CGON) is -27.84% down in the 30-day period. We can see from the shorts that 8.05 million shares have been sold at a short interest cover period of 10.06 day(s).
The consensus price target as assigned by Wall Street analysts is $57.5, which translates to bulls needing to increase their stock price by 65.11% from its current value. Analyst projections state that CGON is forecast to be at a low of $55 and a high of $60.
Cg Oncology Inc (CGON) estimates and forecasts
The year-over-year growth rate is expected to be 203.77%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 144.61k in revenue for the current quarter. 6 analysts expect Cg Oncology Inc to make 148.78k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 529k and 111k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -72.66%. Forecasts for the next quarter put sales growth at 34.04%.
Cg Oncology Inc earnings are expected to increase by -28.22% in 2025, but the outlook is positive 38.86% per year for the next five years.
CGON Dividends
Cg Oncology Inc’s next quarterly earnings report is expected to be released on 2025-Mar-27.
Cg Oncology Inc (NASDAQ:CGON)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.16% of Cg Oncology Inc shares, and 98.38% of them are in the hands of institutional investors. The stock currently has a share float of 104.84%. Cg Oncology Inc stock is held by 208.0 institutions, with DECHENG CAPITAL LLC being the largest institutional investor. By 2024-06-30, it held 8.1903% of the shares, which is about 5.46 million shares worth $172.33 million.
TCG CROSSOVER MANAGEMENT, LLC, with 5.5067% or 3.67 million shares worth $115.87 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.89 shares worth $37.84 million, making up 2.48% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund held roughly 1.56 shares worth around $31.29 million, which represents about 2.05% of the total shares outstanding.
